Hana Pharm Co., Ltd. (293480.KS) Stock

293480.KS logo

Hana Pharm Co., Ltd.

293480.KSSouth Korea
Healthcare

Company profile

Hana Pharm reported revenue of 239.50 billion KRW for fiscal year 2025, up 6.3% from fiscal year 2024, and net income of 8.78 billion KRW. That is a net profit margin of 3.7% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 62.26 billion KRW, up 8.3% from a year before. In Q1 2026 it reported net income of 10.00 billion KRW, against net income of 4.24 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 224.46 billion KRW in fiscal year 2023 to 239.50 billion KRW in fiscal year 2025, 3.3% a year on average.

What stands out

  • Net income fell 58.7% in fiscal year 2025, from 21.25 billion KRW in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Hana Pharm Co., Ltd.

Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Dong-hoon Cho25.29 %25.29%
  • Ye-Rim Cho11.46 %11.46%
  • Hye-rim Cho11 %11.00%
  • Young-ja Lim4.587 %4.59%
  • Hana Pharm Co., Ltd.2.66%

Share of the company, as of May 19, 2026

Leadership

  • Taehong Choi — President, CEO & Director
  • Hong-Joo Yun — Director of Business Department, CFO & Director
  • Elia Cho — Director of Global Department & Director
  • Sang-yeop Kim — Head of New Product Research Lab

How much revenue does Hana Pharm make?

Hana Pharm reported 239.50 billion KRW in revenue for fiscal year 2025, up 6.3% from 225.34 billion KRW in fiscal year 2024. In Q1 2026 revenue was 62.26 billion KRW.

What companies are similar to Hana Pharm?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Samil Pharmaceutical Co.,Ltd (000520.KS), Yungjin Pharm. Co., Ltd. (003520.KS), Ilsung Is Co., Ltd. (003120.KS), Dongwha Pharm.Co.,Ltd (000020.KS).

Has Hana Pharm made a profit in recent years?

Net income by fiscal year: FY2021, 28.01 billion KRW; FY2022, 24.31 billion KRW; FY2023, 22.33 billion KRW; FY2024, 21.25 billion KRW; FY2025, 8.78 billion KRW. It was profitable in each of these years.

How has Hana Pharm's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 196.41 billion KRW; FY2022, 210.84 billion KRW; FY2023, 224.46 billion KRW; FY2024, 225.34 billion KRW; FY2025, 239.50 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
EK-Tower, Seoul, 06162
Phone
82 2 577 7667
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Hana Pharm Co., Ltd. (293480.KS)”, data as of May 19, 2026, https://dataporium.tech/stocks/293480.KS

LinkedInLinkedInXXYouTubeYouTube